![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Rifater, Tebrazid, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682402 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | >90% |
Metabolism | liver |
Elimination half-life | 9 to 10 hours |
Excretion | kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.002.470 |
Chemical and physical data | |
Formula | C5H5N3O |
Molar mass | 123.115 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Pyrazinamide is a medication used to treat tuberculosis.[2] For active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol.[3] It is not generally recommended for the treatment of latent tuberculosis.[2] It is taken by mouth.[1]
Common side effects include nausea, loss of appetite, muscle and joint pains, and rash.[2][4] More serious side effects include gout, liver toxicity, and sensitivity to sunlight.[2] It is not recommended in those with significant liver disease or porphyria.[3] It is unclear if use during pregnancy is safe but it is likely okay during breastfeeding.[3] Pyrazinamide is in the antimycobacterial class of medications.[2] How it works is not entirely clear.[2]
Pyrazinamide was first made in 1936, but did not come into wide use until 1972.[5] It is on the World Health Organization's List of Essential Medicines.[6] Pyrazinamide is available as a generic medication.[2]